CD19 and diffuse large B-cell lymphoma: Lately, CD19-CAR T cell efficacy has been also validated for R/R diffuse large B cell lymphoma (DLBCL) and R/R follicular lymphoma (FL), which highlighted the remarkable and tolerable anti-tumor function [74–76].